VERA THERAPEUTICS INC (VERA) Forecast, Price Target & Analyst Ratings
NASDAQ:VERA • US92337R1014
38.92 USD
+0.07 (+0.18%)
Last: Mar 6, 2026, 02:40 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VERA THERAPEUTICS INC (VERA).
Forecast Snapshot
Consensus Price Target
$76.26
+ 95.95% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$1.28
Revenue Estimate
ChartMill Buy Consensus
83.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$76.26
Upside
+ 95.95%
From current price of $38.92 to mean target of $76.26, Based on 20 analyst forecasts
Low
$33.33
Median
$74.46
High
$105.00
Price Target Revisions
1 Month
-0.21%
3 Months
19.70%
Price Target Summary
20 analysts have analysed VERA and the average price target is 76.26 USD. This implies a price increase of 95.95% is expected in the next year compared to the current price of 38.92.
The average price target has been revised upward by 19.7% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
83.00%
VERA was analyzed by 20 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about VERA.
In the previous month the buy percentage consensus was at a similar level.
VERA was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-19 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-12-19 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-19 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-11 | Wedbush | Maintains | Neutral -> Neutral |
| 2025-12-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-12-05 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-16 | B of A Securities | Initiate | Buy |
| 2025-08-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-04 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2025-06-02 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-06-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-07 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-05-07 | Wedbush | Maintains | Neutral -> Neutral |
| 2025-03-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-02-27 | Guggenheim | Maintains | Buy -> Buy |
| 2025-02-04 | Wolfe Research | Initiate | Outperform |
| 2024-11-21 | Wells Fargo | Initiate | Overweight |
| 2024-11-08 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-28 | Guggenheim | Maintains | Buy -> Buy |
| 2024-10-16 | ScotiaBank | Initiate | Sector Outperform |
| 2024-10-03 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$1.28
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-57.97%
Number of Analysts11
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
1.54%
Next Earnings Summary
VERA is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -1.28 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 445.28% | N/A 122.25% | N/A 102.54% | N/A 32.47% | N/A 23.22% | N/A 9.67% | N/A 12.02% | |||||||
| EBITDA YoY % growth | -11.08M | -47.81M -331.50% | -34.22M 28.43% | N/A -126.53% | N/A -27.63% | -167.065M -68.85% | -315.005M -88.55% | N/A -2.99% | N/A 39.95% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.59M | -48.06M -314.67% | -34.4M 28.42% | -90.9M -164.24% | -102.012M -12.22% | -167.17M -63.87% | -315.473M -88.71% | N/A -7.41% | N/A 27.31% | N/A 108.25% | N/A 1,588.61% | N/A 75.00% | N/A 28.63% | N/A 28.07% | N/A 17.46% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -13.71 | -3.35 75.57% | -2.31 31.04% | -2.75 -19.05% | -4.66 -69.45% | N/A -2.24% | N/A 30.89% | N/A 99.96% | N/A 461,500.00% | N/A 46.47% | N/A 3.46% | N/A 23.15% | N/A 15.76% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.28 -57.97% | -1.36 -13.52% | -1.27 -0.74% | -1.05 24.73% |
| Revenue Q2Q % growth | 7.984M | 24.835M | ||
| EBITDA Q2Q % growth | -79.248M -38.77% | -90.883M -13.69% | -76.723M 8.23% | N/A |
| EBIT Q2Q % growth | -92.929M -62.48% | -99.085M -23.64% | -92.933M -10.72% | -91.671M 2.69% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.99%
EPS Next 5 Year
30.94%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
VERA THERAPEUTICS INC / VERA Forecast FAQ
What is the price target for VERA stock?
20 analysts have analysed VERA and the average price target is 76.26 USD. This implies a price increase of 95.95% is expected in the next year compared to the current price of 38.92.
Can you provide the upcoming earnings date for VERA THERAPEUTICS INC?
VERA THERAPEUTICS INC (VERA) will report earnings on 2026-05-04.
What are the consensus estimates for VERA THERAPEUTICS INC (VERA) next earnings?
The consensus EPS estimate for the next earnings of VERA THERAPEUTICS INC (VERA) is -1.28 USD and the consensus revenue estimate is 0 USD.
How many analysts cover VERA THERAPEUTICS INC (VERA) stock?
The number of analysts covering VERA THERAPEUTICS INC (VERA) is 20.